Correlations of serum microRNA-499A-5P, fibroblast growth factor 9 and inflammatory factor with the severity and prognosis of acute lung injury caused by sepsis

MA Jing; ZHENG Xisheng; LI Changli; ZHAO Congyuan; DONG Zhaogang

doi:10.7619/jcmp.20233049

Journal of Clinical Medicine in Practice > 2024 > 28(8): 55-60. > DOI: 10.7619/jcmp.20233049

MA Jing, ZHENG Xisheng, LI Changli, ZHAO Congyuan, DONG Zhaogang. Correlations of serum microRNA-499A-5P, fibroblast growth factor 9 and inflammatory factor with the severity and prognosis of acute lung injury caused by sepsis[J]. Journal of Clinical Medicine in Practice, 2024, 28(8): 55-60. DOI: 10.7619/jcmp.20233049

Citation:

PDF (1104 KB)

Correlations of serum microRNA-499A-5P, fibroblast growth factor 9 and inflammatory factor with the severity and prognosis of acute lung injury caused by sepsis

Comprehensive ICU, Nanyang Central Hospital of Henan Province, Nanyang, Henan, 473000

More Information

Received Date: September 24, 2023
Revised Date: November 07, 2023
Available Online: May 05, 2024

Graphical Abstract

Abstract

Abstract

Objective
To explore the correlation of serum microRNA-499a-5p (miR-499a-5p), fibroblast growth factor 9 (FGF9) and inflammatory factors with the severity and prognosis of acute lung injury (ALI) caused by sepsis.
Methods
A total of 151 septic patients were selected for the study. They were divided into sepsis with acute lung injury (ALI) group (68 cases) and general sepsis group (83 cases) based on the occurrence of ALI. According to the oxygenation index, septic patients with ALI were further categorized into mild (23 cases), moderate (26 cases), and severe (19 cases) groups. The survival status of septic patients with ALI was assessed within 28 days, and they were divided into good prognosis group (43 cases) and poor prognosis group (25 cases). Additionally, 151 healthy individuals undergoing physical examinations during the same period were selected as the control group. The differences and correlations among miR-499a-5p, FGF9 and inflammatory factors in each group were analyzed. The predictive efficacy of serum miR-499a-5p and FGF9 in patients with sepsis complicated with ALI was analyzed by receiver operating characteristic (ROC) curve.
Results
The levels of miR-499a-5p and FGF9 in the mild, moderate, and severe groups showed significant decrease in a sequential manner, while the inflammatory factors interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP) levels showed significant increase in a sequential manner (P < 0.05). The miR-499a-5p and FGF9 levels in the poor prognosis group were significantly lower than those in the good prognosis group, while the IL-1, IL-6, TNF-α, and CRP levels were significantly higher in the poor prognosis group (P < 0.05). In patients with sepsis and ALI, miR-499a-5p and FGF9 were negatively correlated with IL-1, IL-6, TNF-α, and CRP levels (P < 0.05); miR-499a-5p could positively regulate FGF9 expression (P < 0.05). The diagnostic efficacy of predicting the prognosis of septic patients with ALI using a combination of miR-93 and miR-135a was significantly higher than that of individual prediction (P < 0.05).
Conclusion
The levels of miR-499a-5p, FGF9 and inflammatory factors are associated with the severity and prognosis of ALI in patients with sepsis. The miR-499a-5p and FGF9 may serve as potential biomarkers for the evaluation of prognosis in septic patients with ALI.
- microRNA-499a-5p,
- fibroblast growth factor 9,
- sepsis,
- acute lung injury,
- inflammatory factors

FullText(HTML)

References (24)

References

[1]	石颖, 於江泉, 张文娟. 内质网应激在脓毒症中的研究进展[J]. 实用临床医药杂志, 2023, 27(14): 121-125. doi: 10.7619/jcmp.20230103
[2]	KUMAR V. Pulmonary innate immune response determines the outcome of inflammation during pneumonia and sepsis-associated acute lung injury[J]. Front Immunol, 2020, 11: 1722. doi: 10.3389/fimmu.2020.01722
[3]	WEI B C, CHEN Y, ZHOU W M, et al. Interleukin IL-5 alleviates sepsis-induced acute lung injury by regulating the immune response in rats[J]. Bioengineered, 2021, 12(1): 2132-2139. doi: 10.1080/21655979.2021.1930746
[4]	MIRNA M, PAAR V, REZAR R, et al. MicroRNAs in inflammatory heart diseases and sepsis-induced cardiac dysfunction: a potential scope for the future?[J]. Cells, 2019, 8(11): 1352. doi: 10.3390/cells8111352
[5]	陈玉凤, 孔亚坤, 李江雁, 等. 石斛碱通过miR-499-5p调控糖尿病肾病系膜细胞增殖、上皮间质转化和纤维化[J]. 中国临床药理学杂志, 2023, 39(2): 211-215. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ202302013.htm
[6]	苏维娜, 李晓晶, 张丽丽, 等. MiR-214调控FGF9的表达参与结核分枝杆菌感染肺泡Ⅱ型细胞中PI3K/AKT信号通路的免疫调控作用研究[J]. 中国比较医学杂志, 2021, 31(11): 48-54, 61. doi: 10.3969/j.issn.1671-7856.2021.11.008
[7]	曹钰, 柴艳芬, 邓颖, 等. 中国脓毒症/脓毒性休克急诊治疗指南(2018)[J]. 临床急诊杂志, 2018, 19(9): 567-588. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZLC201809001.htm
[8]	RIVIELLO E D, BUREGEYA E, TWAGIRUMUGABE T. Diagnosing acute respiratory distress syndrome in resource limited settings: the Kigali modification of the Berlin definition[J]. Curr Opin Crit Care, 2017, 23(1): 18-23. doi: 10.1097/MCC.0000000000000372
[9]	李京宴, 田英平, 高恒波, 等. 脓毒症患者继发急性肺损伤的危险因素及早期预测价值[J]. 中国急救医学, 2022, 42(6): 487-492. doi: 10.3969/j.issn.1002-1949.2022.06.005
[10]	王博媛, 胡美. 脓毒症相关miRNA的研究进展[J]. 检验医学与临床, 2023, 20(9): 1298-1302. doi: 10.3969/j.issn.1672-9455.2023.09.026
[11]	高刘炯, 李小磊, 宁文慧, 等. 脓毒症合并急性肺损伤患儿Th1/Th2比值及细胞因子临床意义分析[J]. 检验医学与临床, 2022, 19(21): 2922-2925. https://www.cnki.com.cn/Article/CJFDTOTAL-JYYL202221010.htm
[12]	王金鑫, 饶春晖, 代波, 等. 绿原酸通过TLR4/NF-κB信号通路调控脓毒症大鼠肠上皮细胞屏障功能的研究[J]. 中华全科医学, 2023, 21(3): 405-408. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202303013.htm
[13]	李秋, 姜启栋, 蒋晏, 等. 外周血单核细胞中过氧化物酶体增殖物激活受体α对脓毒症患者炎症因子水平的影响[J]. 中国老年学杂志, 2021, 41(9): 1919-1922. doi: 10.3969/j.issn.1005-9202.2021.09.038
[14]	侯昌权, 韩红伟, 袁女娜, 等. 辛伐他汀纳米粒对脓毒症致ALI小鼠肺组织中TLR9信号通路表达水平及预后的影响[J]. 检验医学与临床, 2021, 18(14): 2029-2033. doi: 10.3969/j.issn.1672-9455.2021.14.012
[15]	何静, 郭玲, 赵庆, 等. 间充质干细胞治疗急性肺损伤的研究进展[J]. 中国临床医生杂志, 2022, 50(6): 651-654. doi: 10.3969/j.issn.2095-8552.2022.06.007
[16]	赵亮, 李金峰, 杨浩, 等. 微小RNA-151-5p通过转化生长因子-β通路参与骨折愈合的早期调控过程[J]. 中华实验外科杂志, 2023, 40(1): 115-118. doi: 10.3760/cma.j.cn421213-20220305-01085
[17]	JIAO Y, ZHANG T, ZHANG C M, et al. Exosomal miR-30d-5p of neutrophils induces M1 macrophage polarization and primes macrophage pyroptosis in sepsis-related acute lung injury[J]. Crit Care, 2021, 25(1): 356. doi: 10.1186/s13054-021-03775-3
[18]	YANG C, WEN K. Predictive value and regulatory mechanism of serum miR-499a-5p on myocardial dysfunction in sepsis[J]. J Cardiothorac Surg, 2021, 16(1): 301. doi: 10.1186/s13019-021-01679-5
[19]	段凌霄, 李芹, 伍长学. MiR-499a-5p靶向MMP-16通过Nrf2信号通路减轻急性呼吸窘迫综合征大鼠的肺损伤[J]. 中国呼吸与危重监护杂志, 2021, 20(7): 487-494. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGHW202107008.htm
[20]	CHEN Y L, DONG S W, TIAN L, et al. Combination of azithromycin and methylprednisolone alleviates Mycoplasma pneumoniae induced pneumonia by regulating miR-499a-5p/STAT3 axis[J]. Exp Ther Med, 2022, 24(3): 578. doi: 10.3892/etm.2022.11515
[21]	贾琪, 高倍瑶, 王丹, 等. 绵羊FGF9基因克隆、生物信息学与表达分析[J]. 中国畜牧杂志, 2023, 59(1): 175-181. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXM202301029.htm
[22]	CHANG M M, WU S Z, YANG S H, et al. FGF9/FGFR1 promotes cell proliferation, epithelial-mesenchymal transition, M2 macrophage infiltration and liver metastasis of lung cancer[J]. Transl Oncol, 2021, 14(11): 101208. doi: 10.1016/j.tranon.2021.101208
[23]	ZHAO F R, ZHANG L, ZHANG M L, et al. FGF9 alleviates the fatty liver phenotype by regulating hepatic lipid metabolism[J]. Front Pharmacol, 2022, 13: 850128. doi: 10.3389/fphar.2022.850128
[24]	LI F D, LIU H, FU J J, et al. Knockdown of long non-coding RNA NEAT1 relieves inflammation of ulcerative colitis by regulating the miR-603/FGF9 pathway[J]. Exp Ther Med, 2022, 23(2): 131.

Cited By

Cited by

Periodical cited type(16)

1.	张磊. 达格列净在NAFLD并CHF患者中的应用效果及可能机制. 新疆医学. 2025(01): 68-72 .
2.	刘凯，陈园园，陈海燕，项学军，乔锐，聂佩. 达格列净对急性心肌梗死合并糖尿病患者经皮冠状动脉介入治疗后糖代谢和心功能的影响. 西北药学杂志. 2024(03): 189-193 .
3.	刘雪龙，侯卫东，田勇. 二甲双胍联合贝那鲁肽对T2DM患者糖脂代谢及SCGN、Asprosin水平的影响. 中国卫生工程学. 2024(03): 413-416 .
4.	周颢，罗英杰. 达格列净联合二甲双胍对肥胖2型糖尿病患者糖脂代谢和微炎症状态的影响. 中国民康医学. 2023(08): 138-141 .
5.	骆景耀，胡义阳. 达格列净治疗2型糖尿病的临床效果及对脂代谢和内脏脂肪的影响. 临床合理用药. 2023(20): 31-33+37 .
6.	张武健，沓世泽，黄东柱. 达格列净对血糖控制不佳的2型糖尿病患者肾脏保护作用的研究. 糖尿病新世界. 2023(10): 10-13 .
7.	秦会娟，侯程浩，张茂杰. 达格列净联合二甲双胍缓释片治疗糖尿病合并慢阻肺稳定期患者的效果分析. 糖尿病新世界. 2023(11): 91-94 .
8.	沈志伟，陈军童，王黎亚. 空腹血糖结合β_2-微球蛋白对糖尿病患者肾功能损伤的诊断效能评价. 中国临床医生杂志. 2023(08): 922-924 .
9.	王丽，苏钢，洪娟，宣小明. 达格列净对早期糖尿病肾病的疗效观察. 中国医师进修杂志. 2023(10): 930-933 .
10.	郑良宏，郑新元. SGLT2抑制剂在2型糖尿病患者治疗中的应用. 糖尿病新世界. 2023(21): 107-109+113 .
11.	王晶，刘易婷，刘哲. 替米沙坦联合瑞舒伐他汀治疗糖尿病合并冠心病对患者外周胰岛素抵抗、糖化血红蛋白、脂蛋白和心肌缺血的影响. 陕西医学杂志. 2022(05): 595-598 .
12.	李枫. 观察达格列净对血糖控制不达标的超重和肥胖2型糖尿病患者血糖控制效果及BMI和肾功能的影响. 糖尿病新世界. 2022(14): 85-88 .
13.	徐爽，童慧昕，梁琳琅，孔媛. 二甲双胍、达格列净、利拉鲁肽联合治疗新诊断超重或肥胖2型糖尿病患者临床疗效及安全性. 临床军医杂志. 2022(12): 1252-1254+1257 .
14.	战玲，宋杰，杨姗姗. 达格列净联合福辛普利治疗高血压合并糖尿病的效果分析. 中国校医. 2022(12): 948-951 .
15.	郑伟. 达格列净或沙格列汀联合二甲双胍治疗2型糖尿病的临床疗效探讨. 糖尿病新世界. 2021(15): 89-92 .
16.	林金城. 达格列净对2型糖尿病合并高尿酸血症患者血糖及尿酸的影响. 医学理论与实践. 2021(24): 4270-4272 .

Other cited types(2)

Get Citation

PDF

XML

Article views (109) PDF downloads (10) Cited by(18)

Turn off MathJax

Article Contents

Abstract

References

Correlations of serum microRNA-499A-5P, fibroblast growth factor 9 and inflammatory factor with the severity and prognosis of acute lung injury caused by sepsis

Abstract

References

Cited by

Periodical cited type(16)

Other cited types(2)

Catalog

Export File

Citation

Format

Content